Mike Cloonan, Sionna Therapeutics CEO
OrbiMed-backed biotech looks to challenge Vertex in cystic fibrosis by 'drugging the undruggable'
A new competitor has emerged from stealth to challenge Vertex in cystic fibrosis.
Sionna Therapeutics, a Sanofi Genzyme spinout, announced its launch with $111 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
